1. Scrip
  2. >>Focus On Asia
  3. >>China

Vabysmo Hopes To Ride New Coverage In China, Data To Expand In Asia

NRDL Listing For Three Indications

 
• By Dexter Jie Yan

Roche's blockbuster ophthalmic drug set for China reimbursement list inclusion in three indications and shows positive interim results in PCV.

Asia ophthalmology
On 28 November, Roche announced Vabysmo’s inclusion in China’s National Reimbursement Drug List (NRDL) from 2025 to 2026. (Shutterstock)

Roche is upping its game for the blockbuster ophthalmic drug Vabysmo (faricimab) in a bid to seize more market share from established contenders in Asia, especially China, where the novel therapy is a latecomer.

On 28 November, the Swiss major announced Vabysmo’s listing in China’s National Reimbursement Drug List (NRDL), which will provide the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

More from Market Access